Navigation Links
Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
Date:5/6/2009

Data from landmark trial provide important insight for physicians in treating heart attack patients

NATICK, Mass., May 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of results from the HORIZONS AMI trial in this week's issue of the New England Journal of Medicine. The HORIZONS AMI trial, sponsored by the Cardiovascular Research Foundation with research grant support from Boston Scientific and The Medicines Company (Nasdaq: MDCO), is designed to evaluate the safety and efficacy of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients undergoing catheter treatment for an acute myocardial infarction (AMI), or heart attack.

With more than 3,000 patients enrolled worldwide, HORIZONS AMI is the largest randomized trial to compare the use of drug-eluting stents (DES) to bare-metal stents (BMS) for the treatment of heart attack patients, a complicated patient population with known increased risks of death and stent thrombosis. The one-year results demonstrated that the TAXUS Express Stent significantly reduced angiographic restenosis and the primary efficacy endpoint of ischemia-driven target lesion revascularization (TLR, or rate of re-intervention of the stented segment) compared to an otherwise identical bare-metal Express(R) Stent control. The primary safety measure showed no difference between the TAXUS Express Stent and the bare-metal Express Stent in overall major adverse cardiovascular events (MACE), or its components, including death, repeat heart attack, stroke or stent thrombosis at one year.

"The HORIZONS AMI trial provided outcomes data showing treatment with a TAXUS paclitaxel-eluting stent had superi
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009).... 30 Cytokine PharmaSciences, Inc.... of CPSI-2364, its orally active, small-molecule i...pro-inflammatory cytokines. Results of the safety... volunteers confirm the safety of this compound in... subjects completed the study, including those rec...
(Date:11/30/2009)...PRNewswire/ -- The Simmons law firm,s Trent Miracl...ing thousands of women that were seriously injured...rol pill manufactured and marketed by Bayer Pharma...istrict Litigation has ordered that all federal Ya...idated and centralized for pretrial litigation in ...
(Date:11/30/2009)... 30 According to Millennium Resear...chnology market intelligence, the nearly $1.2 bill...most 5% over 2008 as patients chose to delay or fo... The market will, however, begin recovery in 2010,...ion growth rates of over 15%. MRG,s facial injecta...
Breaking Medicine Technology:Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2Simmons Firm's Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer 2Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 1Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 2Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 4Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 5Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 6Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 7Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4
...MELBOURNE, Australia, Feb. 11 Phosphagenics,Limit...PGNY) and Nestle,Nutrition (Nestle) today announce... establish the efficacy of Phosphagenics, Phospha ...vancing at three sites in Adelaide,Australia., Ba...ants, the,double-blind phase 2 trial, which is ful...
...BOULDER, Colo., and MONTREAL, Feb. 11 ,Pharmion (N...y announced that,the European Medicines Agency (EM...CD0103, a histone deacetylase (HDAC) inhibitor, as...acute myelogenous leukemia in the,European Union (...duct be,intended for the treatment of life-threate...
Other Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:11/30/2009)...avily more often than younger people, study finds,...- Older people who are problem drinkers consume mo...report finds, possibly because they need more alco... a study released this month, people dependent on ... drinks a week, on average. By contrast, younger a...
(Date:11/30/2009).... Rappa, MD, explores the intricate connection bet...ealing Heart to Soul: One Doctor’s Journey o...9). , Dallas, TX (Vocus) ... let go of negative emotions, whether caused by us...oulders. Oftentimes, this disease of the human spi...
(Date:11/30/2009)..., Nov. 30 Baxa Corporation is spon... "culture of safety" means in today,s pharmacy env...eating a Culture of Safety in Pharmacy ," features... their experiences with culture of safety, what it...d the role of technology in enabling or inhibiting...
(Date:11/30/2009)...v. 30 EMD Serono, an affiliate of ...at it received a refuse to file letter from the US...g Application (NDA) for Cladribine Tablets, EMD Se...n of cladribine, as a therapy for relapsing forms ...ll work closely with the FDA to fully understand F...
(Date:11/30/2009)... A new study has found that 27% of...rance customers have a current intention to shop f...he figure is up from 20% in 2008. Over the past f...een a leading indicator of actual switching patter...itch actually will leave their current insurer for...
Breaking Medicine News(10 mins):Health News:Binge Drinking Not Just a Rite of the Young 2Health News:Healing from the Inside Out: Compelling New Book Explores the Intricate Connection between Body, Soul, and Better Health 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 3Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 2Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 3Health News:More Seniors Considering Health Insurance Switch 2
...sparities Show That,"Geography Matters" for U.S. C... Identified as 10 Bottom States by Key Child Well-...ates of,Louisiana and Vermont may be part of the s... is born and raised can,make a shockingly large di...
...ETAIRIE, La., April 2, 2008 OrthoSynetics(TM), th...ntic and dental practices,worldwide, produces tele...s,and practices -- and this year, the production o..., but for the opportunity to work,and contract wit...
...al attention at any,sign of infection, ROCHESTER,...ds that patients who are 50 or older and take mult...y bowel disease have a higher,risk for developing ...or Crohn,s disease, the most common forms of infla...
...tions are associated with increased risk of lung c...eam led by scientists at The University of Texas M... online edition of Nature Genetics. , "This is th... in M. D. Anderson,s Department of Epidemiology. T...
...dents have been indicted in connection with an $11...ion clinics, Assistant Attorney General,Alice S. F.... Alexander,Acosta of the Southern District of Flo...Carmen Gonzalez,33, were all charged today in fede...
...f Upper,Union Street Veterinary Hospital in Schene...mmit VetPharm,s "The Great Vectra 3D(TM)" $125,000...s multi-level contest and,will receive $25,000 in ...m. There will be one more lucky $25,000,winner in ...
Other Medicine News:Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 2Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 3Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 4Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 5Health News:OrthoSynetics(TM) Brings Ad Production Home to New Orleans 2Health News:Mayo Clinic Identifies Infection Risks for Patients with Inflammatory Bowel Disease 2Health News:Genetic variations raise lung cancer risk for smokers and ex-smokers 2Health News:Genetic variations raise lung cancer risk for smokers and ex-smokers 3Health News:Genetic variations raise lung cancer risk for smokers and ex-smokers 4Health News:Seven Miami-Area Residents Charged in $11 Million Medicare Fraud Scheme 2Health News:Summit VetPharm Announces Second Winner in Its 'Great Vectra 3D(TM)' $125,000 Giveaway 2
Satin-Slip® 10FR Intubating Stylet
Disposable Aluminum 11 1/2" Stylette
Solid Copper Malleable Stylette
S5000N Ultra-Slip™ Stylet
Medicine Products: